HEMP: CBD-induced Biomarkers of Inflammation Reduction in People Living With HIV at the Single Cell Level (cannabis)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05209867|
Recruitment Status : Recruiting
First Posted : January 27, 2022
Last Update Posted : September 16, 2022
People living with HIV (PLWH) are affected by comorbidities appearing to be strongly related to chronic inflammation, a condition characterizing PLWH.
The investigators propose to study the effects of CBD on inflammation in PLWH, and establish the molecular role of different immune cells in this process. The investigators plan to use single cell RNA-sequencing (scRNAseq) to isolate CBD-specific cellular phenotypes from five persons with HIV who will provide blood samples before and after taking CBD.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Inflammation||Drug: CBD oil||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||CBD-induced Biomarkers of Inflammation Reduction in People Living With HIV at the Single Cell Level|
|Actual Study Start Date :||May 1, 2022|
|Estimated Primary Completion Date :||February 2024|
|Estimated Study Completion Date :||February 2024|
Experimental: CBD Intervention
Participants will self-administer CBD daily for 2 months.
Drug: CBD oil
Other Name: Cannabidiol
- Inflammation Reduction [ Time Frame: 2 months ]Fold change before/after CBD in PBMC(Peripheral Blood Mononuclear Cells) cells for MAPK(Mitogen-Activated Protein Kinase) related inflammation genes by measure the change in the expression of genes related to inflammation in cells from the patient's blood before and after administering CBD.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05209867
|United States, Florida|
|University of Florida||Recruiting|
|Gainesville, Florida, United States, 32610|
|Contact: Simone Marini, PhD 352-294-8951 email@example.com|
|Principal Investigator: Simone Marini, PhD|
|Principal Investigator:||Simone Marini, PhD||University of Florida|